Gastric Motility Agents

Primary Prokinetic Options

The American Gastroenterological Association recommends metoclopramide 5-20 mg three to four times daily, taken 30 minutes before meals and at bedtime, for the treatment of gastroparesis 1
The ESPEN ICU guideline recommends intravenous erythromycin 100-250 mg three times daily for 2-4 days as first-line prokinetic therapy for gastric feeding intolerance 2
Domperidone is available in the United States through FDA investigational drug protocol and should be used at a dose of 10-20 mg three to four times daily, with caution against doses above 10 mg three times daily due to risk of QT prolongation 1

For acute gastroparesis or feeding intolerance, the European Society for Clinical Nutrition and Metabolism recommends starting with intravenous erythromycin 100-250 mg three times daily for 2-4 days 2
For chronic gastroparesis requiring longer-term management, the American College of Gastroenterology recommends starting with metoclopramide 5-20 mg three to four times daily 1

Opioids should be withdrawn in gastroparesis patients as they directly impair gastrointestinal motility, and alternative pain management options such as tricyclic antidepressants, SNRIs, or anticonvulsants should be used instead, as recommended by the American Gastroenterological Association 3, 1
Sustained-release formulations should be avoided in patients with gastric motility disorders, and liquid formulations or crushed tablets should be used when applicable, as recommended by the American College of Gastroenterology 4

In chronic intestinal pseudo-obstruction (CIPO), a trial with prokinetics such as metoclopramide, domperidone, erythromycin, octreotide, neostigmine, and prucalopride should always be attempted despite limited efficacy, as recommended by the European Society for Clinical Nutrition and Metabolism 5, 6, 7
In short bowel syndrome, antimotility agents such as loperamide should be used to control stool losses, administered 30 minutes before meals and at bedtime, as recommended by the American Gastroenterological Association 4
In intensive care patients, intravenous erythromycin should be used as first-line prokinetic therapy, with metoclopramide or combination therapy as alternatives, and prokinetics should be discontinued after 3 days due to decreased effectiveness, as recommended by the European Society for Clinical Nutrition and Metabolism 2

Intravenous erythromycin 100 mg–250 mg administered three times daily for a maximum of 2–4 days is recommended as first‑line prokinetic therapy; treatment should be stopped after 3 days because efficacy falls to roughly one‑third after 72 hours. 8

Initiate prokinetic therapy when gastric residual volumes exceed 500 mL within a 6‑hour period, indicating feeding intolerance. 8
Use the intravenous route preferentially in the acute paralytic‑ileus setting because oral absorption is unreliable when gastric motility is severely impaired. 8

Perform cardiac monitoring because both erythromycin and metoclopramide can prolong the QT interval and predispose to arrhythmias. 8
Short‑term erythromycin exposure (24–48 h) has not been linked to alterations in gut microbiota; microbiota changes were observed only after prolonged (≥48 months) therapy in the BLESS trial. 8
Large case series report few adverse effects, although seizures have been documented in neurological patients receiving these agents. 8

If erythromycin fails to achieve adequate gastric emptying, intravenous metoclopramide 10 mg two to three times daily may be used as a second‑line agent. 8
Combination therapy with both metoclopramide and erythromycin is an option when monotherapy is insufficient. 8

When gastric feeding intolerance persists despite prokinetic therapy, switch to post‑pyloric (jejunal) feeding to bypass the paralysed stomach and maintain enteral nutrition. 8

A meta‑analysis of six studies showed that intravenous erythromycin significantly improves enteral feeding tolerance compared with control (risk ratio 0.58; 95 % CI 0.34–0.98; p = 0.04). 8

Autonomic dysfunction in Guillain‑Barré syndrome frequently causes gastroparesis and paralytic ileus, making prokinetic therapy especially relevant. 8
Paralytic ileus may continue beyond the acute phase, requiring ongoing reassessment of feeding tolerance as neurological recovery progresses. 8
In severe, persistent gastroparesis, a venting gastrostomy may be placed to decompress the stomach while jejunal feeding is continued. 9